Physician profile
Paul E Bing
NPI 1376541870
$2,021.33
in general payments reported to CMS, 2019-2025
27 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $88.43 · 2021: $256 · 2022: $568 · 2023: $242 · 2024: $393 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $573.72 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $305.02 | 2020-2025 | Evenity, Repatha, Tezspire |
| Glaxosmithkline, LLC. | $234.57 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $146.23 | 2019-2023 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $124.58 | 2019-2023 | Breztri |
| Pfizer INC. | $97.13 | 2019-2021 | |
| Amarin Pharma, INC. | $72.03 | 2021-2023 | |
| Pacira Therapeutics, INC. | $46.58 | 2019-2021 | |
| Genzyme Corporation | $41.45 | 2019-2024 | |
| Inogen, INC. | $33.47 | 2022 | |
| Mallinckrodt Hospital Products INC. | $32.21 | 2022 | |
| Sumitomo Pharma America, INC. | $30.85 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.98 | 2019 | |
| Nevro Corp. | $25.22 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $20.91 | 2025 | |
| Bausch Health US, LLC | $20.38 | 2019 | |
| Exact Sciences Corporation | $19.48 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.99 | 2024 | Aralast |
| Pacira Pharmaceuticals Incorporated | $18.82 | 2023 | Exparel, Zilretta, Iovera |
| Insmed, INC. | $17.32 | 2023 | Arikayce |
| Electromed, INC. | $16.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2024 | Zoryve |
| Inspire Medical Systems, INC. | $14.18 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $13.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.98 | 2019 | |
| Janssen Biotech, INC. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.